RxDoctor Payments Data

Norma Delgado Buther, MD

Pulmonary Disease · Carolina, PRNPI 1962420786

Payments from drug & device makers

$1,346in general payments, 2019–2025

Across 59 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$426
  • GSK$334
  • Sanofi$142
  • Boehringer Ingelheim$134
  • Mallinckrodt Hospital Products Inc.$100
  • Smith+Nephew$71
  • plus $138 from 3 others

What the payments were for

  • Food & beverage$1,21290%
  • Education$13410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca23$426
GSK16$334
Sanofi6$142
Boehringer Ingelheim6$134
Mallinckrodt Hospital Products Inc.1$100
Smith+Nephew1$71
Gilead2$60
Amgen2$54
Mylan LLC2$24

How this compares

$1,346 in reported general payments places this provider in the 30th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$9,611
Medicare patients
32
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate35$459,919
Trelegy ElliptaFluticasone/Umeclidin/Vilanter584$395,736
Dupixent PenDupilumab42$159,565
Breo ElliptaFluticasone/Vilanterol316$129,853
Fasenra PenBenralizumab20$117,225
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate306$79,021
NucalaMepolizumab21$75,943
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr129$62,106
SymbicortBudesonide/Formoterol Fumarate160$38,268
Stiolto RespimatTiotropium Br/Olodaterol Hcl63$30,681
Breztri AerosphereBudesonide/Glycopyr/Formoterol45$29,463
Albuterol Sulfate HfaAlbuterol Sulfate663$28,023
Spiriva RespimatTiotropium Bromide37$19,585
Famotidine1,183$10,461
Fluticasone Propionate353$8,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta$334$663,6381,050 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$134$510,185135 claims
AstraZenecaSymbicort, Breztri Aerosphere$426$67,731205 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Carolina

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →